Tucatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tucatinib
Accession Number
DB11652  (DB06142)
Type
Small Molecule
Groups
Investigational
Description

Tucatinib has been used in trials studying the treatment of HER2 Positive Breast Cancers and HER2 Positive Metastatic Breast Cancers.

Structure
Thumb
Synonyms
Not Available
External IDs
ARRY-380 / ONT-380
Categories
Not Available
UNII
234248D0HH
CAS number
937263-43-9
Weight
Average: 480.532
Monoisotopic: 480.202222045
Chemical Formula
C26H24N8O2
InChI Key
SDEAXTCZPQIFQM-UHFFFAOYSA-N
InChI
InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
IUPAC Name
N6-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-N4-(3-methyl-4-{[1,2,4]triazolo[1,5-a]pyridin-7-yloxy}phenyl)quinazoline-4,6-diamine
SMILES
CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Tucatinib is a selective, orally-active inhibitor of ErbB-2, a receptor kinase target that has been found to be over-expressed in breast, ovarian and stomach cancers and other cancers. The growth factor receptor tyrosine kinase ErbB-2 plays a major role in controlling cell growth and differentiation.

TargetActionsOrganism
UReceptor tyrosine-protein kinase erbB-2Not AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
51039094
PubChem Substance
347828023
ChemSpider
34995558
ChEMBL
CHEMBL3989868
Wikipedia
Tucatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHER2 Positive Breast Cancers1
1Active Not RecruitingTreatmentHER2 Positive Metastatic Breast Cancers1
1CompletedTreatmentDrug Drug Interaction (DDI)2
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentMalignancies1
1Not Yet RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentHealthy Volunteers1
1, 2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentHER2 Positive Breast Cancers1
2RecruitingTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Carcinoma, Colorectal / Colon Adenocarcinoma / Colorectal Adenocarcinoma / Colorectal Cancers / Colorectal Tumors / ERBB2 Gene Amplification / HER-2 Gene Amplification / HER2/Neu Positive / KRAS wt Allele / Metastatic Cancers / Metastatic Colon Cancer / Neoplasms, Colorectal / NRAS wt Allele / Rectal Adenocarcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Rectal Carcinoma / Stage III Colon Cancer AJCC v7 / Stage III Colorectal Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Colorectal Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Colorectal Cancer AJCC v7 / Stage IV Rectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
2RecruitingTreatmentLeptomeningeal Disease / Metastatic Breast Cancer (MBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.004 mg/mLALOGPS
logP3.87ALOGPS
logP5.25ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)17.08ChemAxon
pKa (Strongest Basic)4.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area110.85 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity148.37 m3·mol-1ChemAxon
Polarizability50.76 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Diarylethers / Triazolopyridines / Aniline and substituted anilines / Phenoxy compounds / Phenol ethers / Aminopyrimidines and derivatives / Toluenes / Pyridines and derivatives / Imidolactams / Triazoles
show 8 more
Substituents
Quinazolinamine / Diaryl ether / Triazolopyridine / Phenoxy compound / Phenol ether / Aniline or substituted anilines / Aminopyrimidine / Toluene / Pyrimidine / Monocyclic benzene moiety
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transmembrane signaling receptor activity
Specific Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, alt...
Gene Name
ERBB2
Uniprot ID
P04626
Uniprot Name
Receptor tyrosine-protein kinase erbB-2
Molecular Weight
137909.27 Da

Drug created on October 20, 2016 14:37 / Updated on May 01, 2019 11:14